Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa (ARQ-MA-000260)

An Open-Label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Study Overview

• Status: Not yet recruiting
• Conditions: Hidradenitis Suppurativa (HS)
• Intervention / Treatment: Drug: Roflumilast 0.3% topical foam

Detailed Description

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that causes painful and inflamed lumps and abscesses often in the underarms, groin and buttocks. The purpose of this study is to assess the safety and efficacy of QD 0.3% topical roflumilast foam in patients with HS over 16 weeks, with or without previous treatment. The drug involved in this study, 0.3% topical roflumilast foam, is investigational.

• Study Type: Interventional
• Enrollment (Estimated): 10
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Harrison Nguyen, MD, MD; Phone Number: 346.771.3990; Email: harrison.nguyen@harrisonderm.com
• Study Contact Backup: Name: Amina Caballero, SCRC; Phone Number: 346.771.3990; Email: amina.caballero@harrisonderm.com

Study Locations

• United States
  • Texas
    • Missouri City, Texas, United States, 77459
      • Harrison Dermatology
      • Contact: Harrison Nguyen, MD, MD; Phone Number: 346.771.3990; Email: harrison.nguyen@harrisonderm.com
      • Contact: Amina Caballero, SCRC; Phone Number: 346.771.3990; Email: amina.caballero@harrisonderm.com
      • Principal Investigator: HARRISON NGUYEN, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female subjects aged 12 years or older at time of consent (or assent).
• Participants and/or legal guardians are legally competent to sign and give informed consent or assent (for adolescents).
• Diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 3 months.
• Diagnosis of HS (Hurley Stage I or II) with a total abscess and inflammatory nodule (AN) count of at least 4 to ≤10, with no draining tunnels at screening and baseline visits, affecting at least one distinct anatomical region.
• Agreement to NOT use topical and systemic antibiotics and intralesional steroids for treatment of HS during the study.
• Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study.
• Subjects who have had surgery in the treatment area must be at least 3 months post-procedure (applies to deroofing/marsupialization or excision, not incision and drainage).
• Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline/Day 1 and agree to use at least one highly effective or barrier method of contraception throughout the study.

Females of non-childbearing potential must be premenarchal, postmenopausal (≥12 months spontaneous amenorrhea), or surgically sterile.

-In good health as judged by the Investigator based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)/legal guardian(s) must be reliable and capable of adhering to the protocol and visit schedule.

Exclusion Criteria:

• Medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
• Inability to discontinue prohibited medications or treatments before Baseline or during the study.
• Presence of draining tunnels at Screening or Baseline.
• Unwillingness to refrain from prolonged sun exposure or tanning beds/other artificial light-emitting devices for 4 weeks before Baseline and during the study.
• Skin conditions other than HS that could interfere with evaluation of study medication.
• Conditions in the treatment area that could confound efficacy measurements.
• Known allergy to excipients in roflumilast foam.
• Use of oral roflumilast (Daxas® or Daliresp®) within 4 weeks before Baseline.
• History of severe depression, suicidal ideation, or suicidal behavior at Screening/Baseline.
• Pregnant, planning pregnancy during the study, or breastfeeding.
• Previous treatment with roflumilast cream or foam or current roflumilast use for another indication expected to continue during the study.
• Major surgery within 4 weeks before Baseline or planned during the study.
• History of chronic alcohol or drug abuse within 6 months before Screening.
• History of cancer within 5 years, except fully treated basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix.
• Parent(s)/legal guardian(s) or subjects unable to communicate, read, or understand the local language, or otherwise unsuitable for participation in the Investigator's opinion.
• Family members of the clinical study site, study staff, sponsor, or family members of enrolled subjects living in the same household.
• Known or suspected severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Roflumilast Foam 0.3; Experimental: Roflumilast 0.3% topical foam Roflumilast 0.3% topical foam to be applied QD to all active fields for the duration of the 16-week trial. Interventions: Drug: Roflumilast 0.3% topical foam	Drug: Roflumilast 0.3% topical foam; Roflumilast 0.3% topical foam applied once daily (QD) to all active hidradenitis suppurativa lesions for 16 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16	Mean change from baseline in the total abscess and inflammatory nodule (AN) count. AN count is the total number of abscesses and inflammatory nodules assessed at baseline and week 16.	Baseline and Week 16

Collaborators and Investigators

• Sponsor: Harrison Dermatology
• Investigators: Principal Investigator: HARRISON NGUYEN, MD

Publications and helpful links

Helpful Links

• https://medlineplus.gov/hidradenitissuppurativa.html
• https://dailymed.nlm.nih.gov/dailymed/

Study record dates

Study Major Dates

• Study Start (Estimated): August 10, 2026
• Primary Completion (Estimated): March 10, 2028
• Study Completion (Estimated): December 10, 2028

Study Registration Dates

• First Submitted: July 1, 2026
• First Submitted That Met QC Criteria: July 7, 2026
• First Posted (Actual): July 8, 2026

Study Record Updates

• Last Update Posted (Actual): July 8, 2026
• Last Update Submitted That Met QC Criteria: July 7, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: HS
• Additional Relevant MeSH Terms: Infections; Skin Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Sweat Gland Diseases; Skin Diseases, Bacterial; Skin Diseases, Infectious; Suppuration; Hidradenitis; Skin and Connective Tissue Diseases; Hidradenitis Suppurativa; Roflumilast
• Other Study ID Numbers: ARQ-MA-000260

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No